Shaily Q1 FY27: consolidated PAT rises 17% YoY to ₹48 Cr as margins expand

Shaily Engineering Plastics' consolidated revenue came in at ₹280.67 Cr, up 13.8% YoY (₹246.69 Cr) and 18.5% QoQ (₹236.82 Cr), with consolidated PAT of ₹48.01 Cr, up 16.7% YoY (₹41.12 Cr) and 19.6% QoQ (₹40.16 Cr). Neither this quarter nor the year-ago quarter carries an exceptional item, so the growth is on a clean, like-for-like basis. On a standalone (parent-only) basis the print is stronger still — revenue ₹274.78 Cr and PAT ₹52.47 Cr, running ₹4.46 Cr ahead of the consolidated PAT. The gap between the two bases is fully explained by one overseas subsidiary: its interim financials, not yet reviewed by the auditor, show a ₹1.97 Cr net loss on ₹1.43 Cr of revenue for the quarter, which the auditor's limited-review report flags as immaterial to the group. On profitability, operating margin (revenue less all costs excluding finance cost and depreciation) expanded to 29.6% this quarter from 27.7% both a year ago and last quarter — roughly 190 bps of YoY expansion — while consolidated net margin improved to 17.1% from 16.5% YoY. That expansion lines up with the healthcare-led mix shift (pen injectors, plus emerging consumer-electronics and semiconductor-tray lines) management has been pointing to. Management gave no formal quantitative guidance on the Q4 FY26 call — only a qualitative outlook of "profitable and sustainable growth" from new healthcare capacity and "strong potential for margin improvement"; this quarter's ~190 bps YoY OPM expansion is directionally consistent with that framing, so it reads as on-track rather than a clear beat or miss against a number. No management press release accompanying this filing was available in our records, so this read rests solely on the results statement and the prior concall. A web search for Street consensus on this print turned up only a generic near-term price-target note contingent on the quarter "meeting expectations," with no PAT or revenue estimate attached, so vsStreet is marked unknown rather than guessed. Separately, the company allotted 40,155 ESOP shares during the quarter, taking paid-up equity to 4,59,95,248 shares of ₹2 each, and the board that approved these results also fixed a dividend record date. Going into H2 FY27, the two markers to watch are the pace of Semaglutide pen-injector capacity utilisation — management has spoken of reaching full utilisation over the next two years — and progress on the Abu Dhabi healthcare capacity build-out; whether the OPM can hold above the 29% now printed, against continued capacity ramp-up costs, will be the key margin checkpoint next quarter.